Muhammed Yasir Demirci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammed Yasir Demirci has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Betul Okuyan
Marmara Üniversitesi
3 shared publications - Mesut Sancar
Marmara Üniversitesi
3 shared publications - Betül Özgan
Marmara University
1 shared publication - Buket Erturk Sengel
Department of Infectious Diseases and Clinical Microbiology, University of Marmara, İstanbul, Turkey
1 shared publication - Bulent Mutlu
Cardiology Department, Marmara University Faculty of Medicine , Istanbul
1 shared publication - Cüneyd Enver
Marmara Univ, Fac Pharm, Dept Clin Pharm, Istanbul, Turkiye
1 shared publication
Latest Publications
- Open Access
- 7 April 2026
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 48 (4) , 1548-1558
Impact of clinical pharmacist-led behavioural theory-based discharge service to promote medication adherence in patients with acute coronary syndrome: a randomised controlled trial
Introduction: Medication non-adherence is common in patients with acute coronary syndrome (ACS) and may increase the risk of cardiac readmissions and mortality. Aim: To evaluate the effect of a clinical pharmacist-led, behavioural theory-based discharge service designed to promote medication adherence on 30-day cardiac readmissions (primary outcome) and on clinical, humanistic, and healthcare utilisation outcomes over 360 days in patients with ACS. Method: In this single-centre, parallel-group randomised controlled trial, adult patients hospitalised with ACS were assigned by permuted block randomisation (block size 8) to the intervention or control group. The intervention comprised a clinical pharmacist-led, behavioural theory-based discharge service to promote medication adherence. The intervention consisted of medication reconciliation, medication review and patient counselling based on components of the behaviour change technique taxonomy and Health Belief Model. The primary outcome was 30-day hospital readmission for cardiac reasons. Secondary outcomes included all-cause and cardiac readmissions, emergency department visits, all-cause and cardiac mortality, medication adherence, LDL (low-density lipoprotein) target attainment, and quality of life over 360 days. Results: A total of 167 patients were analysed (intervention: n = 80; control: n = 87). The primary outcome occurred in 0/80 (0.0%) in the intervention group versus 5/87 (5.7%) in the control group (risk difference − 5.7%, 95% CI − 12.8 to 2.1%; p >0.050). Over 360 days, the control group had higher adjusted odds of cardiac readmission (aOR 4.4; 95% CI 1.2–16.0; p = 0.027), all-cause readmission (aOR 3.7; 95% CI 1.1–11.7; p = 0.029), and non-adherence at 30 days (aOR 2.4; 95% CI 1.1–5.2; p = 0.028). At 180 days, the control group had lower adjusted odds of LDL target attainment (aOR 0.4; 95% CI 0.2–0.9; p = 0.038). Conclusion: This intervention reduced 30-day cardiac readmission, but the effect was not statistically significant. According to findings of secondary outcomes, this behavioural theory-based discharge service at discharge might be effective in reducing healthcare utilisation in the long term and improving the short-term target for medication adherence in patients with acute coronary syndrome. Trial registration: ClinicalTrials.gov NCT05153707.
- 7 April 2026
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 48 (4) , 1548-1558
Open AccessImpact of clinical pharmacist-led behavioural theory-based discharge service to promote medication adherence in patients with acute coronary syndrome: a randomised controlled trial
Introduction: Medication non-adherence is common in patients with acute coronary syndrome (ACS) and may increase the risk of cardiac readmissions and mortality. Aim: To evaluate the effect of a clinical pharmacist-led, behavioural theory-based discharge service designed to promote medication adherence on 30-day cardiac readmissions (primary outcome) and on clinical, humanistic, and healthcare utilisation outcomes over 360 days in patients with ACS. Method: In this single-centre, parallel-group randomised controlled trial, adult patients hospitalised with ACS were assigned by permuted block randomisation (block size 8) to the intervention or control group. The intervention comprised a clinical pharmacist-led, behavioural theory-based discharge service to promote medication adherence. The intervention consisted of medication reconciliation, medication review and patient counselling based on components of the behaviour change technique taxonomy and Health Belief Model. The primary outcome was 30-day hospital readmission for cardiac reasons. Secondary outcomes included all-cause and cardiac readmissions, emergency department visits, all-cause and cardiac mortality, medication adherence, LDL (low-density lipoprotein) target attainment, and quality of life over 360 days. Results: A total of 167 patients were analysed (intervention: n = 80; control: n = 87). The primary outcome occurred in 0/80 (0.0%) in the intervention group versus 5/87 (5.7%) in the control group (risk difference − 5.7%, 95% CI − 12.8 to 2.1%; p >0.050). Over 360 days, the control group had higher adjusted odds of cardiac readmission (aOR 4.4; 95% CI 1.2–16.0; p = 0.027), all-cause readmission (aOR 3.7; 95% CI 1.1–11.7; p = 0.029), and non-adherence at 30 days (aOR 2.4; 95% CI 1.1–5.2; p = 0.028). At 180 days, the control group had lower adjusted odds of LDL target attainment (aOR 0.4; 95% CI 0.2–0.9; p = 0.038). Conclusion: This intervention reduced 30-day cardiac readmission, but the effect was not statistically significant. According to findings of secondary outcomes, this behavioural theory-based discharge service at discharge might be effective in reducing healthcare utilisation in the long term and improving the short-term target for medication adherence in patients with acute coronary syndrome. Trial registration: ClinicalTrials.gov NCT05153707.
- 1 April 2024
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 21 (2) , 152-158
Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic
Objectives: Drug -related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist -led medication review in hospitalized probable patients with coronavirus disease -2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in T & uuml;rkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician's acceptance rate of clinical pharmacists' recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug -related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.
- 1 April 2024
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 21 (2) , 152-158
Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic
Objectives: Drug -related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist -led medication review in hospitalized probable patients with coronavirus disease -2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in T & uuml;rkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician's acceptance rate of clinical pharmacists' recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug -related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.
- 10 November 2021
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 44 (1) , 247-255
Factors associated with Turkish pharmacists’ intention to receive COVID-19 vaccine: an observational study
Background Pharmacists have been taking part in vaccination services during the COVID-19 pandemic. However, research identifying pharmacists’ intention to get COVID-19 vaccine is limited. Aim The objective of this study was to determine the intention to receive COVID-19 vaccine and to identify the factors related to it based on the Health Belief Model framework among Turkish pharmacists. Method This is an observational study conducted between December 2020 and January 2021. The online survey was sent to all hospital and community pharmacists working in Turkey. Transtheoretical Model of Behaviour Change and Health Belief Model were used for the development of the questionnaire. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with the intention to receive COVID-19 vaccine. Results Among all participants (n = 961), 74.7% had an intention to receive the COVID-19 vaccine. In model 1, perceived susceptibility, perceived severity, perceived benefits, and perceived barriers were associated with their intention to receive the COVID-19 vaccine (p < 0.05). In model 2, the intention to receive COVID-19 vaccine was associated with being male, years of experience in the professional field, not having contracted COVID-19, having a pharmacy staff who had contracted COVID-19, and having had received seasonal flu shot within the previous year (p < 0.05). Conclusion This study highlights the factors related to the intention of the pharmacists to receive COVID-19 vaccines. Health Belief Model is the strongest predictor for vaccination intention and could be used to develop behavioural change techniques to promote vaccination.
- 10 November 2021
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 44 (1) , 247-255
Factors associated with Turkish pharmacists’ intention to receive COVID-19 vaccine: an observational study
Background Pharmacists have been taking part in vaccination services during the COVID-19 pandemic. However, research identifying pharmacists’ intention to get COVID-19 vaccine is limited. Aim The objective of this study was to determine the intention to receive COVID-19 vaccine and to identify the factors related to it based on the Health Belief Model framework among Turkish pharmacists. Method This is an observational study conducted between December 2020 and January 2021. The online survey was sent to all hospital and community pharmacists working in Turkey. Transtheoretical Model of Behaviour Change and Health Belief Model were used for the development of the questionnaire. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with the intention to receive COVID-19 vaccine. Results Among all participants (n = 961), 74.7% had an intention to receive the COVID-19 vaccine. In model 1, perceived susceptibility, perceived severity, perceived benefits, and perceived barriers were associated with their intention to receive the COVID-19 vaccine (p < 0.05). In model 2, the intention to receive COVID-19 vaccine was associated with being male, years of experience in the professional field, not having contracted COVID-19, having a pharmacy staff who had contracted COVID-19, and having had received seasonal flu shot within the previous year (p < 0.05). Conclusion This study highlights the factors related to the intention of the pharmacists to receive COVID-19 vaccines. Health Belief Model is the strongest predictor for vaccination intention and could be used to develop behavioural change techniques to promote vaccination.